INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

NCT00322712 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-02-05

Study results available
· View outcomes & findings →

Summary

Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Conditions

Sponsors & Collaborators

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Fa-Chyi Lee, MD · University of New Mexico

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-12-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322712 on ClinicalTrials.gov